{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:15:04Z","timestamp":1758672904217,"version":"3.44.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The goal of treatment for Crohn\u2019s disease (CD) is to achieve mucosal or transmural healing, and biomarker measurements are useful in monitoring disease activity and guiding treatment. This study aimed to investigate the utility of a new urinary biomarker, prostaglandin E-major urinary metabolite (PGE-MUM), in assessing CD activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study involved 87 patients with CD who underwent endoscopic examination and measurements of 4 biomarkers: Prostaglandin E-major urinary metabolite, fecal calprotectin (FC), leucine-rich \u03b12 glycoprotein (LRG), and C-reactive protein (CRP). Endoscopic activity was assessed by the Simple Endoscopic Score for Crohn\u2019s Disease (SES-CD). Correlations between the CD activity index (CDAI) and SES-CD with the 4 biomarkers were analyzed, and receiver-operating characteristic (ROC) analyses were performed to predict SES-CD\u2005\u2267\u20053.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All 4 biomarkers showed significant correlations with both CDAI and SES-CD. The cutoff (area under the curve [AUC]) values for predicting SES-CD\u2005\u2265\u20053 were as follows: PGE-MUM, 25.2 \u00b5g\/g Cr (0.800); FC, 257\u00a0mg\/kg (0.816); LRG, 11.8 \u00b5g\/mL (0.748); and CRP, 0.22\u00a0mg\/dL (0.656). Subgroup analysis revealed significant correlations between PGE-MUM and SES-CD in both the L1 (small intestine only) and L2\u2005+\u2005L3 (including large intestine) groups, with correlation coefficients of 0.654 and 0.586, respectively. In the L1 group, ROC analysis revealed that, among the 4 biomarkers, PGE-MUM had the highest AUC for predicting SES-CD\u2005\u2265\u20053, with a cutoff (AUC) of 33.1 \u00b5g\/g Cr (0.861).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PGE-MUM is a biomarker that can reflect endoscopic activity in patients with CD and may be particularly useful in small intestinal lesions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izaf025","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:39:17Z","timestamp":1747827557000},"page":"2420-2428","source":"Crossref","is-referenced-by-count":0,"title":["Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn\u2019s Disease Activity: A Prospective Cross-Sectional Study"],"prefix":"10.1093","volume":"31","author":[{"given":"Natsuki","family":"Ishida","sequence":"first","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tamura","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Takebe","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-1097","authenticated-orcid":false,"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"5","key":"2025092307422137700_CIT0001","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1053\/j.gastro.2015.08.001","article-title":"Genetics of inflammatory bowel diseases","volume":"149","author":"McGovern","year":"2015","journal-title":"Gastroenterology."},{"issue":"12","key":"2025092307422137700_CIT0002","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1136\/gutjnl-2021-326575","article-title":"Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts","volume":"71","author":"Adolph","year":"2022","journal-title":"Gut."},{"issue":"8","key":"2025092307422137700_CIT0003","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41579-019-0213-6","article-title":"Microbial genes and pathways in inflammatory bowel disease","volume":"17","author":"Schirmer","year":"2019","journal-title":"Nat Rev Microbiol."},{"issue":"8","key":"2025092307422137700_CIT0004","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/gut.2005.084061","article-title":"Phenotype at diagnosis predicts recurrence rates in Crohn\u2019s disease","volume":"55","author":"Wolters","year":"2006","journal-title":"Gut."},{"issue":"6","key":"2025092307422137700_CIT0005","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn\u2019s disease digestive damage score, the L\u00e9mann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"2025092307422137700_CIT0006","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025092307422137700_CIT0007","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"4","key":"2025092307422137700_CIT0008","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"issue":"5","key":"2025092307422137700_CIT0009","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bpg.2016.09.005","article-title":"Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy","volume":"30","author":"Levy","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol."},{"issue":"8","key":"2025092307422137700_CIT0010","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.mib.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025092307422137700_CIT0011","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025092307422137700_CIT0012","doi-asserted-by":"publisher","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","article-title":"Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease","volume":"11","author":"Yasutomi","year":"2021","journal-title":"Sci Rep."},{"issue":"6","key":"2025092307422137700_CIT0013","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.14309\/ajg.0000000000002127","article-title":"Serum leucine-rich \u03b12 glycoprotein: a novel biomarker for transmural inflammation in Crohn\u2019s disease","volume":"118","author":"Takenaka","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2025092307422137700_CIT0014","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/ibd\/izac230","article-title":"Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for evaluating clinical and endoscopic disease activity in inflammatory bowel disease","volume":"29","author":"Shimoyama","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025092307422137700_CIT0015","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF00915791","article-title":"Regulation of the immune response by prostaglandins","volume":"3","author":"Goodwin","year":"1983","journal-title":"J Clin Immunol."},{"issue":"4","key":"2025092307422137700_CIT0016","first-page":"614","article-title":"Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis","volume":"90","author":"Raab","year":"1995","journal-title":"Am J Gastroenterol."},{"key":"2025092307422137700_CIT0017","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ncomms1181","article-title":"Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance","volume":"2","author":"Chinen","year":"2011","journal-title":"Nat Commun."},{"key":"2025092307422137700_CIT0018","first-page":"191","article-title":"Simplified immunoassays of prostaglandin E main metabolite in human urine","volume":"11","author":"Inagawa","year":"1983","journal-title":"Adv Prostaglandin Thromboxane Leukot Res."},{"issue":"7","key":"2025092307422137700_CIT0019","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/MIB.0000000000000062","article-title":"Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis","volume":"20","author":"Arai","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025092307422137700_CIT0020","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/jgh.15782","article-title":"Prostaglandin E-major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase","volume":"37","author":"Sakurai","year":"2022","journal-title":"J Gastroenterol Hepatol."},{"issue":"1","key":"2025092307422137700_CIT0021","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025092307422137700_CIT0022","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcla.21640","article-title":"Significant increase of prostaglandin E major urinary metabolite in male smokers a screening study of age and gender differences using a simple radioimmunoassay","volume":"28","author":"Okayasu","year":"2014","journal-title":"J Clin Lab Anal."},{"key":"2025092307422137700_CIT0023","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rmed.2016.11.017","article-title":"Increased levels of prostaglandin E major urinary metabolite (PGE MUM) in chronic fibrosing interstitial pneumonia","volume":"122","author":"Horikiri","year":"2017","journal-title":"Respir Med."},{"issue":"11","key":"2025092307422137700_CIT0024","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2006.07.015","article-title":"Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia","volume":"4","author":"Johnson","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2025092307422137700_CIT0025","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1940-6207.CAPR-13-0040","article-title":"Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women","volume":"6","author":"Kim","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"2025092307422137700_CIT0026","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/cancers11060768","article-title":"Prostaglandin E-major urinary metabolite (PGE-MUM) as a tumor marker for lung adenocarcinoma","volume":"11","author":"Kawamoto","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2025092307422137700_CIT0027","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0016-5085(90)90958-4","article-title":"Gliadin challenge-induced jejunal prostaglandin E2 secretion in celiac disease","volume":"99","author":"Lav\u00f6","year":"1990","journal-title":"Gastroenterology."},{"issue":"12","key":"2025092307422137700_CIT0028","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/BF01295815","article-title":"Colonic transport of water and electrolytes in a patient with secretory diarrhea due to collagenous colitis","volume":"28","author":"Rask-Madsen","year":"1983","journal-title":"Dig Dis Sci."},{"issue":"4 Pt 2","key":"2025092307422137700_CIT0029","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology."},{"issue":"3","key":"2025092307422137700_CIT0030","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"2025092307422137700_CIT0031","first-page":"584","article-title":"Development of fully automated chemiluminescent enzyme immunoassay system for measurement of prostaglandin E major urinary metabolites (PGE-MUM)","volume":"42","author":"Katagiri","year":"2017","journal-title":"Jpn J Clin Lab Autom."},{"issue":"1","key":"2025092307422137700_CIT0032","doi-asserted-by":"publisher","first-page":"9898","DOI":"10.1038\/s41598-023-37145-6","article-title":"Utility of a rapid assay for prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis","volume":"13","author":"Hagiwara","year":"2023","journal-title":"Sci Rep."},{"issue":"1","key":"2025092307422137700_CIT0033","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5217\/ir.2023.00092","article-title":"Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn\u2019s disease activity confirmed by balloon-assisted enteroscopy","volume":"22","author":"Kawamoto","year":"2024","journal-title":"Intest Res"},{"issue":"6","key":"2025092307422137700_CIT0034","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","article-title":"Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study","volume":"56","author":"Shinzaki","year":"2021","journal-title":"J Gastroenterol."},{"issue":"9","key":"2025092307422137700_CIT0035","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","article-title":"IOIBD technical review on endoscopic indices for Crohn\u2019s disease clinical trials","volume":"65","author":"Vuitton","year":"2016","journal-title":"Gut."},{"issue":"4","key":"2025092307422137700_CIT0036","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ecco-jcc\/jjab182","article-title":"Faecal calprotectin from ileostomy output is sensitive and specific for the prediction of small bowel inflammation in patients with Crohn\u2019s disease","volume":"16","author":"Daoud","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025092307422137700_CIT0037","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology."},{"issue":"1","key":"2025092307422137700_CIT0038","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00535-020-01737-0","article-title":"Significance of endoscopic deep small bowel evaluation using balloon-assisted enteroscopy for Crohn\u2019s disease in clinical remission","volume":"56","author":"Takabayashi","year":"2021","journal-title":"J Gastroenterol."},{"issue":"3","key":"2025092307422137700_CIT0039","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000007758","article-title":"Significant increase in prostaglandin E-main urinary metabolite by laxative administration: comparison with ulcerative colitis","volume":"61","author":"Fujiwara","year":"2000","journal-title":"Digestion."},{"issue":"8","key":"2025092307422137700_CIT0040","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1097\/MIB.0000000000000449","article-title":"Correlation of the endoscopic and magnetic resonance scoring systems in the deep small intestine in Crohn\u2019s disease","volume":"21","author":"Takenaka","year":"2015","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf025\/63265748\/izaf025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/9\/2420\/63265748\/izaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/9\/2420\/63265748\/izaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:45:19Z","timestamp":1758627919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/9\/2420\/8140081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf025","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,21]]}}}